Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 3;9(6):e98623. doi: 10.1371/journal.pone.0098623

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Forget et al

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

To reach serum levels of CSF1 similar to breast cancer patients and determine that effect on TEM expansion, PBS or CSF1 (20 ng/ml) was intravenously injected into non-tumor bearing wild type C57Bl/6 female mice every other day for a total of three treatments. Bone marrow and atrial blood was collected and immunostained with CD45 and Tie2 antibodies (for bone marrow) or CD11b, CD31, Gr-1, and Tie2 antibodies (for blood). There was no difference in the percentage of TEMs in the bone marrow of the PBS- and CSF1-treated mice. In peripheral blood, CSF1 treatment significantly reduced the percent of CD11b+/CD31+/Gr-1lo/Tie2- cells while significantly increasing CD11b+/CD31+/Gr-1lo/Tie2+ TEMs. N = 5 mice per group and results represent the mean ± SEM of percent total CD45+ and CD45+/Tie2+ cells from bone marrow, and the percent of CD11b+/CD31-/Gr-1lo/Tie2- and CD11b+/CD31-/Gr-1lo/Tie2+ TEMs in peripheral blood.